All News

Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014.

In an abrupt about-face, the Obama administration halted its ill-timed effort to launch an overhaul of the Medicare Part D program and announced it would not pursue changes in some key rules as proposed earlier this year.

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.

Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital investments in biotechnology.

Historically, pharmaceutical companies have leveraged remote patient monitoring (RPM) in a very limited way to improve data collection in clinical trials.

Interaction between pharma representatives and doctors has traditionally been a paper-based and static experience in which the representative enters with one-quarter of a campaign in hand and then tries to deliver the remaining pieces three more times through the year.

Just think what Frankenstein could do with this product. It looks like skin, feels like skin, but it’s not skin. It’s LabSkin, a facsimile, being manufactured by a clinical research group Venn Life Sciences.

A milestone of sorts took place on Monday March 3 when MarijuanaDoctors.com began airing a television commercial that looks to be the first ever marijuana commercial on a major TV network.

The Myelin Repair Foundation is more than just a policy precedent - it’s also emerging as the stimulus behind a future cure for MS.

When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process for generic drugs, and combat the agency’s backlog of drug applications.

Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases.

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.

Not long ago, I was privy to a discussion taking place in a large drug development services company.

Following the U.S. ban on all imports from Ranbaxy’s Toansa, India, facility, the drug maker has voluntarily suspended all shipments of bulk drugs from its manufacturing facilities both at Toansa and Dewas, in order to reassess quality controls at the plants.

The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.

In less than a decade, online video marketing has moved from a standing start to become an essential part of the digital marketing mix

This week (February 28), Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention.

Any pricing or revenue management initiative is only as good as the information on which it is based.

Europe’s main pharma industry bodies - EFPIA, EGA, EuropaBio, AESGP and EUCOPE - have issued a joint statement to express concern about “the increasing financial burden of regulatory costs incurred since the adoption of the pharmacovigilance package in 2010?.

In this short video, Brianna Cayo-Cotter, Change.org’s managing director of communications, talks to Pharm Exec about how advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy, all fueled by the hour-to-hour passion of living with a disease.

Four class representatives have been added to a class-action gender-discrimination employment suit originally filed last May against Merck & Co. in New Jersey.

Cuts in healthcare costs due to post-recession austerity programs mean favorable Health Technology Assessments (HTAs) are becoming crucial to the successful market launch of pharmaceuticals in Europe.

America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide.

To mark its 25th year in recognizing female leadership in the tough competitive ranks of biopharma, the Healthcare Businesswomen’s Association (HBA) is opting for a breakout triple play.

Despite notable successes in preventing and mitigating short supplies of important medicines, the drug shortage crisis still disrupts medical treatment and gives drug manufacturers a bad name.

As the United Kingdom debate about whether to stay in the European Union becomes more bitter and intense, an insight into how EU membership impacts on medicines and pharmaceuticals has appeared from a British politician who was until recently the UK Government Adviser on Life Sciences, George Freeman.

Accenture has launched the latest version of its annual study of the biopharmaceutical industry.